# IMPACT Therapeutics

Source: https://onco.cc/companies/impact-therapeutics/  
OnCo record `impact-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

IMPACT is a Shanghai biotech built around DNA damage response drugs; its PARP inhibitor senaparib met its phase 3 endpoint as maintenance in ovarian cancer and is approved in China.

## Summary

IMPACT Therapeutics, headquartered in Shanghai, develops inhibitors of the DNA damage response. Its PARP inhibitor senaparib (IMP4297) improved progression-free survival as first-line maintenance in advanced ovarian cancer in the phase 3 FLAMES trial and gained Chinese approval, and its Wee1 and ATR inhibitors follow in earlier trials. Its trials are registered on ClinicalTrials.gov under IMPACT as lead sponsor.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Impact Therapeutics, Inc.; IMPACT Therapeutics (Shanghai)
- Tags: ctgov-sponsor
- HQ: Shanghai
- Type: biotech
- Website: https://www.impacttherapeutics.com

## Sources

- Official website: https://www.impacttherapeutics.com
- ClinicalTrials.gov: trials led by Impact Therapeutics, Inc.: https://clinicaltrials.gov/search?lead=Impact%20Therapeutics%2C%20Inc.
- Wikidata: https://www.wikidata.org/wiki/Q140046067

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)

---
JSON: https://onco.cc/api/v1/entities/impact-therapeutics.json